Latest news with #KNithyanandaReddy
Time of India
27-05-2025
- Business
- Time of India
Aurobindo Pharma shares in focus after Q4 profit dips marginally to Rs 903 cr
Aurobindo Pharma shares are likely to be in focus on Tuesday after the Hyderabad-based drug manufacturer reported a marginal dip in its consolidated net profit for the March 2025 quarter. The company posted a profit after tax (PAT) of Rs 903 crore in Q4FY25, slightly lower than Rs 907 crore reported in the same quarter of the previous fiscal. Despite the minor decline in bottom-line performance, Aurobindo's revenue from operations rose to Rs 8,382 crore in the March quarter, up from Rs 7,580 crore in the year-ago period, indicating robust topline growth. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More For the full year ended March 31, 2025, the company delivered a 10% year-on-year increase in PAT at Rs 3,484 crore, compared to Rs 3,169 crore in FY24. Annual revenue also grew significantly to Rs 31,724 crore, up from Rs 29,002 crore the previous year. "We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said. Live Events The drug firm's European operations continue to perform exceptionally well, moving steadily towards the USD 1 billion revenue milestone, Reddy added. Also read: EQT firm Sagility B.V. to offload up to Rs 2,671 crore stake in Sagility India via offer for sale Aurobindo Pharma share price history Over the past year, Aurobindo Pharma's stock has declined by 4.51%. The year-to-date (YTD) performance shows a drop of 12.73%, while the six-month return stands at a negative 4.05%. In contrast, the stock gained 9.06% over the last three months. However, it has slipped 3.16% in the past month. Aurobindo Pharma shares closed 1.4% lower at Rs 1,179.35 on the BSE on Tuesday. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
&w=3840&q=100)
Business Standard
26-05-2025
- Business
- Business Standard
Aurobindo Pharma Q4 results: Profit dips to ₹903 cr, revenue up 11%
Aurobindo Pharma on Monday reported a marginal dip in its consolidated profit after tax to Rs 903 crore for the fourth quarter ended March 2025. The Hyderabad-based drug maker posted a profit after tax (PAT) of Rs 907 crore in the January-March quarter of FY24. Its total revenue from operations stood at Rs 8,382 crore for the fourth quarter compared to Rs 7,580 crore in the year-ago period, Aurobindo Pharma said in a regulatory filing. For the full year ended March 31, 2025, the company said its PAT rose 10 per cent to Rs 3,484 crore against Rs 3,169 crore in FY24. The total revenue from operations rose to Rs 31,724 crore last fiscal from Rs 29,002 crore in 2023-24. "We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said. The drug firm's European operations continue to perform exceptionally well, moving steadily towards the USD 1 billion revenue milestone, he added. "Backed by our ongoing capacity enhancements we remain firmly positioned to sustain our trajectory and create long-term value for our stakeholders," Reddy said. Aurobindo Pharma shares on Monday ended 1.43 per cent down at Rs 1,179.35 apiece on BSE.
&w=3840&q=100)
Business Standard
26-05-2025
- Business
- Business Standard
Aurobindo Pharma Q4 PAT falls marginally to ₹903 cr, revenue up 10%
Aurobindo Pharma Limited reported a marginal decline of 0.5 per cent in its net profit to ₹903 crore in the fourth quarter of financial year 2024–25 (Q4FY25), compared to ₹907 crore in the same period last year. The company's revenue from operations rose 10.6 per cent year-on-year (YoY) to ₹8,382 crore during the quarter, with growth seen across key business segments. Revenue from US formulations grew by 13.5 per cent YoY to ₹4,072 crore ($470 million), while Europe formulations posted stronger growth of 17.2 per cent YoY to ₹2,147 crore (€236 million). 'Our European operations continue to perform exceptionally well, moving steadily towards the $1 billion revenue milestone. Backed by our ongoing capacity enhancements, we remain firmly positioned to sustain our trajectory and create long-term value for our stakeholders,' said K Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma. Revenue from Growth Markets declined 7.8 per cent YoY to ₹786 crore ($91 million), primarily due to moderated performance in select regions. The antiretroviral (ARV) segment recorded robust growth, with revenue rising 29.4 per cent YoY to ₹308 crore ($36 million), contributing 3.7 per cent to consolidated revenue. Active Pharmaceutical Ingredient (API) revenue increased by 5.0 per cent YoY to ₹1,069 crore ($124 million), accounting for 12.8 per cent of consolidated revenue. Operational and financial metrics EBITDA before R&D stood at ₹2,202 crore, with a margin of 26.3 per cent EBITDA before forex and other income was ₹1,792 crore, with a 21.4 per cent margin R&D expenditure, including depreciation, was ₹423 crore, amounting to 5.0 per cent of total revenue During the quarter, the company received final approval for five ANDAs from the US Food and Drug Administration (USFDA), including two previously tentatively approved. Earnings per share (EPS) for the quarter stood at ₹15.56, both basic and diluted. Domestic formulation sales stood at ₹56 crore during the quarter. The company's API revenue in dollar terms rose 0.7 per cent YoY to $124 million, while ARV revenue rose 24.1 per cent YoY to $36 million.
Time of India
26-05-2025
- Business
- Time of India
Aurobindo Q4FY25 net profit slips marginally to Rs 903 crore
Representative image HYDERABAD: Aurobindo Pharma on Monday reported a marginal 0.5 per cent drop in consolidated net profit for the fourth quarter ended 31 March 2025, at Rs 903 crore from Rs 907 crore in the corresponding period of last year. This was despite a 10.6 per cent rise in revenue from operations for Q4FY25 at Rs 8,382 crore from Rs 7,580 crore in Q4FY24. However, for the entire fiscal year 2024-25 (FY25), the company clocked a nearly 10 per cent rise in net profit at Rs 3,484 crore from Rs 3,169 crore in FY24 on a 9.4 per cent rise in consolidated revenue from operations of Rs 31,724 crore in FY25 as compared to Rs 29,002 crore in FY24. The company said revenue from formulations grew 12.2 per cent in FY25 to Rs 27,388 crore from Rs 24,419 crore in FY24. While revenues from US formulations grew nearly 7 per cent to Rs 14,815 crore from Rs 13,867 crore, that from Europe formulations rose 16.6 per cent to Rs 8,356 crore from Rs 7,166 crore, and from growth markets went up 26.3 per cent to Rs 3,180 crore in FY25 from Rs 2,517 crore. However, for Q4FY25, growth markets revenues declined nearly 8 per cent to Rs 786 crore from Rs 852 crore in Q4FY24. The quarter saw US formulations increase 13.5 per cent to Rs 4,072 crore and European formulations rise 17.2 per cent to Rs 2,147 crore. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo Aurobindo Pharma vice-chairman & managing director K Nithyananda Reddy said the company's European operations are moving towards the $1 billion revenue milestone even as the company is betting on capacity enhancements to sustain its trajectory. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
26-05-2025
- Business
- Time of India
Aurobindo Pharma Q4 net dips marginally to Rs 903 cr; revenue at Rs 8,382 cr
Aurobindo Pharma on Monday reported a marginal dip in its consolidated profit after tax to Rs 903 crore for the fourth quarter ended March 2025. The Hyderabad-based drug maker posted a profit after tax (PAT) of Rs 907 crore in the January-March quarter of FY24. Its total revenue from operations stood at Rs 8,382 crore for the fourth quarter compared to Rs 7,580 crore in the year-ago period, Aurobindo Pharma said in a regulatory filing. For the full year ended March 31, 2025, the company said its PAT rose 10 per cent to Rs 3,484 crore against Rs 3,169 crore in FY24. The total revenue from operations rose to Rs 31,724 crore last fiscal from Rs 29,002 crore in 2023-24. "We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said. Live Events The drug firm's European operations continue to perform exceptionally well, moving steadily towards the USD 1 billion revenue milestone, he added. "Backed by our ongoing capacity enhancements we remain firmly positioned to sustain our trajectory and create long-term value for our stakeholders," Reddy said. Aurobindo Pharma shares on Monday ended 1.43 per cent down at Rs 1,179.35 apiece on BSE. ETMarkets WhatsApp channel )
